Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Trial crawled time : 12:01 save search
DuPont to Participate at the J.P. Morgan 2021 Industrials Conference
Published: 2021-03-10 (Crawled : 12:01) - prnewswire.com
DD | News | $73.09 0.72% -0.81% 2.2M
|
Process Industries
|
| O: 0.87%
H: 1.23%
C: 0.51%
trial conference
Balchem Corporation to Present at the J.P. Morgan Industrials Conference on March 15, 2021
Published: 2021-03-09 (Crawled : 12:01) - globenewswire.com
BCPC | $143.97 -1.13% -1.15% 63K
|
Process Industries
|
| O: 0.39%
H: 2.22%
C: 1.25%
trial
Universal Stainless to Present at Cowen and Company 42nd Annual Aerospace/Defense & Industrials Conference on February 11th
Published: 2021-02-09 (Crawled : 12:01) - globenewswire.com
USAP | $26.215 4.32% 4.14% 160K
|
Non-Energy Minerals
|
| O: 0.24%
H: 7.51%
C: 6.17%
defense spac trial space
Atea Pharmaceuticals Announces First Patient Dosed in Phase 2 Virology Trial of AT-527 in Outpatient Setting
Published: 2021-02-04 (Crawled : 12:01) - globenewswire.com
AVIR | $3.71 -0.8% -0.81% 250K
|
Health Technology
|
| O: 0.52%
H: 2.5%
C: -7.63%
phase 2 trial at-527 set
Sio Gene Therapies Announces First Patient Dosed in Clinical Trial of AXO-AAV-GM2 in Patients with Tay-Sachs and Sandhoff Disease (GM2 Gangliosidosis)
Published: 2021-02-03 (Crawled : 12:01) - globenewswire.com
SIOX | $0.478 -20.5% 40K
|
Health Technology
|
| O: 5.76%
H: 0.68%
C: -3.4%
disease gene therapies trial therapy aav9 gene therapy
INmune Bio, Inc. Announces XPro1595 Found to Decrease Neuroinflammation and Neurodegeneration Biomarkers in Patients with Alzheimer’s Disease in Phase 1b Trial
Published: 2021-01-21 (Crawled : 12:01) - globenewswire.com
INMB | $8.51 -7.0% -7.52% 150K
|
Health Technology
|
| O: 14.65%
H: 4.13%
C: -29.31%
disease alzheimer trial phase 1b phase 2b alzheimer’s alzheimer's disease alzheimer's biomarkers
Rockwell Medical Announces Dosing of First Patient in Pivotal Triferic® Phase 3 Trial by Partner, Wanbang Biopharmaceuticals, in China
Published: 2021-01-13 (Crawled : 12:01) - globenewswire.com
RMTI | $1.48 -0.67% -0.68% 160K
|
Health Technology
|
| O: 0.0%
H: 10.17%
C: 5.93%
china biopharma phase 3 trial
Metacrine Reports Positive Results from Phase 1 Trial of MET642
Published: 2020-12-17 (Crawled : 12:01) - globenewswire.com
MTCR | $0.5814 -5.14% 84K
|
Health Technology
|
| O: 4.18%
H: 2.64%
C: -5.19%
results positive results positive trial phase 3 phase 1 phase 2 met642
Anavex Life Sciences Announces ANAVEX®2-73 (Blarcamesine) Meets Primary and Secondary Endpoints in Placebo-Controlled U.S. Phase 2 Clinical Trial for the Treatment of Adult Patients with Rett Syndrome
Published: 2020-12-15 (Crawled : 12:01) - globenewswire.com
AVXL | $4.065 -1.34% -1.35% 1.3M
|
Health Technology
|
| O: 20.42%
H: 2.08%
C: -4.16%
life science trial phase 2 anavex®2-73 anavex syndros rett syndrome
uniQure Presents Late-Breaking Data from the HOPE-B Pivotal Trial of Etranacogene Dezaparvovec Gene Therapy in Patients with Hemophilia B at the 62nd Annual Meeting of the American Society of Hematology
Published: 2020-12-08 (Crawled : 12:01) - globenewswire.com
QURE | $4.67 -0.64% -0.64% 830K
|
Health Technology
|
| O: 2.09%
H: 1.15%
C: -1.53%
therapy gene therapy trial gene therapies
Evelo Biosciences Completes Enrollment to Interim Target in Phase 2 Trial Evaluating EDP1815 for the Treatment of Psoriasis
Published: 2020-12-03 (Crawled : 12:01) - globenewswire.com
EVLO | $0.3165 -87.39% 710K
|
Health Technology
|
| O: -0.6%
H: 4.0%
C: 0.4%
trial treatment phase 2 psoriasis enroll
Borqs Technologies Signed Official Agreement for 5G Industrial Park Project in South Taihu New Area of Zhejiang Province, China
Published: 2020-12-02 (Crawled : 12:01) - globenewswire.com
BRQS | $0.43 -41.86% 1.4M
|
Technology Services
|
| O: 2.78%
H: 1.8%
C: -1.8%
5g china trial
Cara Therapeutics Completes Full Enrollment in KARE Phase 2 Trial of Oral KORSUVA™ in Atopic Dermatitis Patients with Moderate-to-Severe Pruritus
Published: 2020-12-02 (Crawled : 12:01) - globenewswire.com
CARA | $0.7475 5.43% 5.15% 180K
|
Health Technology
|
| O: 0.2%
H: 2.31%
C: 1.22%
dermatitis trial phase 2 atopic dermatitis enroll
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.